{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T13:39:53Z","timestamp":1761831593002,"version":"build-2065373602"},"reference-count":61,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009032","name":"Pfizer UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009032","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013956","name":"Birmingham and the Black Country Comprehensive Local Research Network","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013956","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002066","name":"GlaxoSmithKline foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002066","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.jacl.2017.10.011","type":"journal-article","created":{"date-parts":[[2017,11,13]],"date-time":"2017-11-13T10:45:57Z","timestamp":1510569957000},"page":"44-55","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["A comparison of the effects of low- and high-dose atorvastatin on lipoprotein metabolism and inflammatory cytokines in type 2 diabetes: Results from the Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA) randomized trial"],"prefix":"10.1016","volume":"12","author":[{"given":"Handrean","family":"Soran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yifen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Safwaan","family":"Adam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarza","family":"Siahmansur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan H.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan D.","family":"Schofield","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"See","family":"Kwok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Gittins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"France","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naveed","family":"Younis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.Martin","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul N.","family":"Durrington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin K.","family":"Rutter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2017.10.011_bib1","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2017.10.011_bib2","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(08)60104-X","article-title":"Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis","volume":"371","author":"Kearney","year":"2008","journal-title":"Lancet"},{"issue":"Suppl 2","key":"10.1016\/j.jacl.2017.10.011_bib3","doi-asserted-by":"crossref","first-page":"S378","DOI":"10.2337\/dc09-S344","article-title":"Should all diabetic patients be treated with a statin?","volume":"32","author":"Kamari","year":"2009","journal-title":"Diabetes Care"},{"year":"2014","series-title":"Cardiovascular Disease: Risk Assessment and Reduction, Including Lipid Modification: Clinical guideline [CG181]","key":"10.1016\/j.jacl.2017.10.011_bib4"},{"key":"10.1016\/j.jacl.2017.10.011_bib5","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Stone","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2017.10.011_bib6","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1007\/s00125-009-1454-0","article-title":"Cardiovascular risk assessment scores for people with diabetes: a systematic review","volume":"52","author":"Chamnan","year":"2009","journal-title":"Diabetologia"},{"key":"10.1016\/j.jacl.2017.10.011_bib7","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jacl.2015.02.003","article-title":"National lipid association recommendations for patient-centered management of dyslipidemia: part 1\u2013full report","volume":"9","author":"Jacobson","year":"2015","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2017.10.011_bib8","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1093\/eurheartj\/ehu107","article-title":"The ACC\/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC\/EAS guidelines for the management of dyslipidaemias 2011","volume":"35","author":"Ray","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2017.10.011_bib9","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/j.1464-5491.2010.03139.x","article-title":"Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA): a randomized double-blind placebo-controlled trial of high- vs. low-dose atorvastatin(1)","volume":"28","author":"Rutter","year":"2011","journal-title":"Diabet Med"},{"key":"10.1016\/j.jacl.2017.10.011_bib10","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.atherosclerosis.2015.01.039","article-title":"New insights into the pathophysiology of dyslipidemia in type 2 diabetes","volume":"239","author":"Taskinen","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2017.10.011_bib11","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/MOL.0000000000000318","article-title":"Diabetic dyslipidaemia","volume":"27","author":"Soran","year":"2016","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.jacl.2017.10.011_bib12","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1042\/CS20120304","article-title":"Small dense LDL is more susceptible to glycation than more buoyant LDL in type 2 diabetes","volume":"124","author":"Younis","year":"2013","journal-title":"Clin Sci (Lond)"},{"issue":"Suppl","key":"10.1016\/j.jacl.2017.10.011_bib13","doi-asserted-by":"crossref","first-page":"S237","DOI":"10.1194\/jlr.R800033-JLR200","article-title":"Phospholipase A2 structure\/function, mechanism, and signaling","volume":"50","author":"Burke","year":"2009","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2017.10.011_bib14","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1124\/jpet.105.085522","article-title":"Influence of atorvastatin on apolipoprotein E and AI kinetics in patients with type 2 diabetes","volume":"315","author":"Bach-Ngohou","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jacl.2017.10.011_bib15","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0021-9150(02)00428-8","article-title":"The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease","volume":"167","author":"Soedamah-Muthu","year":"2003","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2017.10.011_bib16","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1161\/CIRCULATIONAHA.113.000962","article-title":"Translation of high-density lipoprotein function into clinical practice: current prospects and future challenges","volume":"128","author":"Rosenson","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2017.10.011_bib17","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/MOL.0b013e328355ca25","article-title":"HDL functionality","volume":"23","author":"Soran","year":"2012","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.jacl.2017.10.011_bib18","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/MOL.0000000000000194","article-title":"How HDL protects LDL against atherogenic modification: paraoxonase 1 and other dramatis personae","volume":"26","author":"Soran","year":"2015","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.jacl.2017.10.011_bib19","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1172\/JCI83475","article-title":"Serum amyloid A impairs the antiinflammatory properties of HDL","volume":"126","author":"Han","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jacl.2017.10.011_bib20","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.arcmed.2011.05.002","article-title":"Lower serum paraoxonase-1 activity is related to higher serum amyloid a levels in metabolic syndrome","volume":"42","author":"Kappelle","year":"2011","journal-title":"Arch Med Res"},{"key":"10.1016\/j.jacl.2017.10.011_bib21","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1253\/circj.CJ-09-0706","article-title":"Inflammation in atherosclerosis: transition from theory to practice","volume":"74","author":"Libby","year":"2010","journal-title":"Circ J"},{"key":"10.1016\/j.jacl.2017.10.011_bib22","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.2174\/138161212799504803","article-title":"Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials","volume":"18","author":"Antonopoulos","year":"2012","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.jacl.2017.10.011_bib23","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.diabres.2005.10.025","article-title":"Serum CRP levels are equally elevated in newly diagnosed type 2 diabetes and impaired glucose tolerance and related to adiponectin levels and insulin sensitivity","volume":"72","author":"Yuan","year":"2006","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.jacl.2017.10.011_bib24","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1161\/ATVBAHA.108.163303","article-title":"Adiponectin decreases C-reactive protein synthesis and secretion from endothelial cells: evidence for an adipose tissue-vascular loop","volume":"28","author":"Devaraj","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2017.10.011_bib25","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1210\/jc.2010-2364","article-title":"Adiponectin is associated with favorable lipoprotein profile, independent of BMI and insulin resistance, in adolescents","volume":"96","author":"Magge","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jacl.2017.10.011_bib26","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jacc.2006.08.061","article-title":"Adiponectin and cardiovascular disease: response to therapeutic interventions","volume":"49","author":"Han","year":"2007","journal-title":"J Am Coll Cardiol"},{"year":"1999","series-title":"Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Report of a WHO Consultation","key":"10.1016\/j.jacl.2017.10.011_bib27"},{"key":"10.1016\/j.jacl.2017.10.011_bib28","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1093\/clinchem\/38.5.658","article-title":"International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. II. Evaluation and selection of candidate reference materials","volume":"38","author":"Albers","year":"1992","journal-title":"Clin Chem"},{"key":"10.1016\/j.jacl.2017.10.011_bib29","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","article-title":"Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge","volume":"18","author":"Friedewald","year":"1972","journal-title":"Clin Chem"},{"key":"10.1016\/j.jacl.2017.10.011_bib30","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1515\/CCLM.2008.254","article-title":"Use of the TLX ultracentrifuge for the isolation of different density lipoproteins and effects of freeze\/thawing of human plasma before ultracentrifugation","volume":"46","author":"Charlton-Menys","year":"2008","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.jacl.2017.10.011_bib31","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1373\/clinchem.2005.063412","article-title":"Semiautomated method for determination of serum paraoxonase activity using paraoxon as substrate","volume":"52","author":"Charlton-Menys","year":"2006","journal-title":"Clin Chem"},{"key":"10.1016\/j.jacl.2017.10.011_bib32","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/0021-9150(90)90029-I","article-title":"Investigation of lipid transfer in human serum leading to the development of an isotopic method for the determination of endogenous cholesterol esterification and transfer","volume":"80","author":"Channon","year":"1990","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2017.10.011_bib33","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1161\/ATVBAHA.109.199158","article-title":"The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages","volume":"30","author":"de la Llera-Moya","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"year":"1996","series-title":"Practical Longitudinal Data Analysis","author":"Hand","key":"10.1016\/j.jacl.2017.10.011_bib34"},{"key":"10.1016\/j.jacl.2017.10.011_bib35","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1037\/a0012850","article-title":"Comparisons of methods for multiple hypothesis testing in neuropsychological research","volume":"23","author":"Blakesley","year":"2009","journal-title":"Neuropsychology"},{"key":"10.1016\/j.jacl.2017.10.011_bib36","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1136\/bmj.326.7404.1423","article-title":"Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis","volume":"326","author":"Law","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.jacl.2017.10.011_bib37","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2017.10.011_bib38","first-page":"2975","article-title":"Cholesterol, not just cardiovascular risk, is important in deciding who should receive statin treatment","volume":"36","author":"Soran","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2017.10.011_bib39","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"32","author":"Reiner","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2017.10.011_bib40","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1258\/acb.2011.010277","article-title":"Apolipoprotein B100 is a better treatment target than calculated LDL and non-HDL cholesterol in statin-treated patients","volume":"48","author":"Soran","year":"2011","journal-title":"Ann Clin Biochem"},{"key":"10.1016\/j.jacl.2017.10.011_bib41","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1373\/clinchem.2008.111401","article-title":"Targets of statin therapy: LDL cholesterol, non-HDL cholesterol, and apolipoprotein B in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS)","volume":"55","author":"Charlton-Menys","year":"2009","journal-title":"Clin Chem"},{"key":"10.1016\/j.jacl.2017.10.011_bib42","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.jacl.2016.07.008","article-title":"An evidence-based analysis of the National Lipid Association recommendations concerning non-HDL-C and apoB","volume":"10","author":"Sniderman","year":"2016","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2017.10.011_bib43","first-page":"915","article-title":"Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity","volume":"320","author":"Steinberg","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2017.10.011_bib44","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1111\/j.1742-4658.2007.05699.x","article-title":"Glycation of low-density lipoprotein results in the time-dependent accumulation of cholesteryl esters and apolipoprotein B-100 protein in primary human monocyte-derived macrophages","volume":"274","author":"Brown","year":"2007","journal-title":"FEBS J"},{"key":"10.1016\/j.jacl.2017.10.011_bib45","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1001\/jama.2011.860","article-title":"Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis","volume":"305","author":"Preiss","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2017.10.011_bib46","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials","volume":"375","author":"Sattar","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2017.10.011_bib47","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s00125-015-3802-6","article-title":"Effect of atorvastatin on glycaemia progression in patients with diabetes: an analysis from the Collaborative Atorvastatin in Diabetes Trial (CARDS)","volume":"59","author":"Livingstone","year":"2016","journal-title":"Diabetologia"},{"key":"10.1016\/j.jacl.2017.10.011_bib48","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/1479164110383063","article-title":"Small-dense LDL and LDL glycation in metabolic syndrome and in statin-treated and non-statin-treated type 2 diabetes","volume":"7","author":"Younis","year":"2010","journal-title":"Diab Vasc Dis Res"},{"key":"10.1016\/j.jacl.2017.10.011_bib49","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1515\/jpem-2015-0365","article-title":"Lipoprotein-associated phospholipase A2 activity and low-density lipoprotein subfractions after a 2-year treatment with atorvastatin in adolescents with type 1 diabetes","volume":"29","author":"Krebs","year":"2016","journal-title":"J Pediatr Endocrinol Metab"},{"key":"10.1016\/j.jacl.2017.10.011_bib50","doi-asserted-by":"crossref","first-page":"609","DOI":"10.4330\/wjc.v7.i10.609","article-title":"Lipoprotein-associated phospholipase A2 prognostic role in atherosclerotic complications","volume":"7","author":"Maiolino","year":"2015","journal-title":"World J Cardiol"},{"key":"10.1016\/j.jacl.2017.10.011_bib51","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1177\/2047487316682186","article-title":"Genetic invalidation of Lp-PLA2 as a therapeutic target: large-scale study of five functional Lp-PLA2-lowering alleles","volume":"24","author":"Gregson","year":"2017","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jacl.2017.10.011_bib52","first-page":"CD008226","article-title":"Lipid-lowering efficacy of atorvastatin","author":"Adams","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jacl.2017.10.011_bib53","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1001\/jama.294.19.2437","article-title":"High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial","volume":"294","author":"Pedersen","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2017.10.011_bib54","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1161\/CIRCULATIONAHA.113.002670","article-title":"Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis","volume":"128","author":"Boekholdt","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2017.10.011_bib55","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1136\/jmedgenet-2016-103966","article-title":"Meta-analysis of genome-wide association studies of HDL cholesterol response to statins","volume":"53","author":"Postmus","year":"2016","journal-title":"J Med Genet"},{"key":"10.1016\/j.jacl.2017.10.011_bib56","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.atherosclerosis.2003.08.025","article-title":"Phenotype-dependent and -independent actions of rosuvastatin on atherogenic lipoprotein subfractions in hyperlipidaemia","volume":"171","author":"Caslake","year":"2003","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2017.10.011_bib57","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.plipres.2015.08.003","article-title":"Effect of statin therapy on paraoxonase-1 status: a systematic review and meta-analysis of 25 clinical trials","volume":"60","author":"Ferretti","year":"2015","journal-title":"Prog Lipid Res"},{"key":"10.1016\/j.jacl.2017.10.011_bib58","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ahj.2016.07.005","article-title":"Cholesterol efflux capacity: an introduction for clinicians","volume":"180","author":"Anastasius","year":"2016","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacl.2017.10.011_bib59","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.atherosclerosis.2016.07.897","article-title":"Impact of statin therapy on plasma adiponectin concentrations: a systematic review and meta-analysis of 43 randomized controlled trial arms","volume":"253","author":"Chrusciel","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2017.10.011_bib60","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ijcard.2014.09.028","article-title":"Reduction of C-reactive protein is not associated with reduced cardiovascular risk and mortality in patients treated with statins. A meta-analysis of 22 randomized trials","volume":"177","author":"Savarese","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacl.2017.10.011_bib61","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1007\/s00125-015-3586-8","article-title":"Effect of atorvastatin on C-reactive protein and benefits for cardiovascular disease in patients with type 2 diabetes: analyses from the collaborative atorvastatin diabetes trial","volume":"58","author":"Soedamah-Muthu","year":"2015","journal-title":"Diabetologia"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287417304713?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287417304713?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T13:34:33Z","timestamp":1761831273000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287417304713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S1933287417304713"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2017.10.011","relation":{},"ISSN":["1933-2874"],"issn-type":[{"type":"print","value":"1933-2874"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A comparison of the effects of low- and high-dose atorvastatin on lipoprotein metabolism and inflammatory cytokines in type 2 diabetes: Results from the Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA) randomized trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2017.10.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 National Lipid Association. All rights reserved.","name":"copyright","label":"Copyright"}]}}